Eli Lilly Invests $6 Billion in Alabama Plant for Obesity Pill Production
Eli Lilly is committing $6 billion to construct a state-of-the-art manufacturing facility in Huntsville, Alabama, with operations slated to begin by 2032. The plant will specialize in producing small-molecule synthetic and peptide medicines, including orforglipron—an experimental obesity pill anticipated to secure FDA approval in early 2026.
This marks the company’s third U.S. facility announcement this year, part of a broader $27 billion expansion strategy across four domestic sites. The project is expected to generate 3,000 construction jobs and 450 permanent roles for skilled professionals in engineering, science, and operations.
The MOVE aligns with growing political pressure to onshore pharmaceutical production, reducing reliance on imported active ingredients. Eli Lilly’s investment underscores the accelerating demand for metabolic treatments and the infrastructure required to support them.
